Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19220988 | DISPENSER AND METHOD OF USE THEREOF | May 2025 | October 2025 | Allow | 4 | 1 | 0 | No | No |
| 19204235 | RADIOPHARMACEUTICAL COMPOSITIONS FOR LOW TOXICITY ACTINIUM IN TARGETED RADIONUCLIDE THERAPY | May 2025 | August 2025 | Allow | 3 | 0 | 1 | No | No |
| 19002866 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | December 2024 | September 2025 | Allow | 8 | 2 | 0 | No | No |
| 18788060 | NANO-DELIVERY CARRIER FOR TARGETED TUMOR ADMINISTRATION AND APPLICATION THEREOF | July 2024 | November 2024 | Allow | 3 | 0 | 0 | No | No |
| 18732203 | COMPOSITIONS FOR TREATMENT OF DISCOGENIC PAIN, AND PROCESSES FOR MAKING AND USING THE SAME | June 2024 | December 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18665612 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | May 2024 | December 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18609128 | DRIED NANOPARTICLE COMPOSITIONS | March 2024 | October 2024 | Allow | 7 | 1 | 0 | No | No |
| 18587211 | SURFACE GRADIENT CROSS-LINKING METHOD OF ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE AND THE APPLICATION THEREOF | February 2024 | February 2026 | Allow | 24 | 2 | 0 | No | No |
| 18405670 | EYE DROP COMPOSITION | January 2024 | November 2024 | Allow | 10 | 1 | 0 | No | No |
| 18403636 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE | January 2024 | August 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18543199 | SOLID SUBSTRATES FOR PROMOTING CELL AND TISSUE GROWTH | December 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18524148 | HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-PLATINUM CHEMOPROTECTANT AGENT | November 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18516052 | Solid Drug Tablets for Implantable Drug Delivery Devices | November 2023 | June 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18501774 | QUATERNARY DISINFECTANT COMPOSITION WITH ANIONIC SCALE INHIBITING AGENT | November 2023 | December 2025 | Allow | 26 | 3 | 0 | No | No |
| 18289215 | MAPPING NANOPARTICLES | November 2023 | December 2025 | Allow | 26 | 4 | 0 | No | No |
| 18381351 | DISPENSER AND METHOD OF USE THEREOF | October 2023 | October 2024 | Allow | 11 | 0 | 0 | No | No |
| 18286675 | Radiopharmaceuticals at Different Activity Reference Times | October 2023 | August 2025 | Allow | 22 | 2 | 1 | No | No |
| 18476396 | METHOD FOR TREATING A BIOLOGICALLY CONTAMINATED SURFACE | September 2023 | October 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18355360 | CONFORMAL COATING OF BIOLOGICAL SURFACES | July 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18221300 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | July 2023 | September 2024 | Allow | 15 | 1 | 0 | No | No |
| 18341337 | MICROBIOTA SEQUENCE VARIANTS OF TUMOR-RELATED ANTIGENIC EPITOPES | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18211938 | NANOPARTICLE PROBES AND METHODS OF MAKING AND USE THEREOF | June 2023 | May 2025 | Allow | 23 | 2 | 0 | No | No |
| 18201864 | ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | May 2023 | September 2024 | Allow | 16 | 1 | 0 | No | No |
| 18322417 | SINGLE- AND MIXED-METAL NANOPARTICLES, NANOPARTICLE CONJUGATES, DEVICES FOR MAKING NANOPARTICLES, AND RELATED METHODS OF USE | May 2023 | December 2024 | Allow | 19 | 2 | 0 | No | No |
| 18310706 | DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAME | May 2023 | June 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18303530 | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONSIVE BIOPOLYMER NETWORKS | April 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18134247 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | April 2023 | November 2024 | Allow | 19 | 1 | 0 | No | No |
| 18130336 | NANOPARTICLE PHARMACEUTICAL DELIVERY SYSTEM | April 2023 | February 2025 | Allow | 23 | 3 | 0 | No | No |
| 18121527 | TARGETING THE INNATE IMMUNE SYSTEM TO INDUCE LONG-TERM TOLERANCE AND TO RESOLVE MACROPHAGE ACCUMULATION IN ATHEROSCLEROSIS | March 2023 | February 2025 | Allow | 23 | 2 | 0 | No | No |
| 18176231 | DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAME | February 2023 | June 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18172094 | [161Tb]-BASED RADIOPEPTIDES | February 2023 | September 2024 | Allow | 19 | 3 | 0 | Yes | No |
| 18019564 | Fluorescently-Traceable Amino Acid Derivative And Preparation Methods And Use Thereof | February 2023 | March 2026 | Allow | 37 | 0 | 1 | Yes | No |
| 18016459 | TUMOR STROMA IMAGING AGENT AND PREPARATION METHOD THEREOF | January 2023 | January 2026 | Allow | 36 | 0 | 0 | No | No |
| 18152137 | RADIOTHERAPY GEL AND METHOD OF PREPARING THE SAME | January 2023 | September 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18004827 | CONTRAST AGENTS FOR DETECTION OF ENZYME ACTIVITIES BASED ON MELANIN SYNTHESIS | January 2023 | October 2025 | Allow | 33 | 0 | 0 | No | No |
| 18146158 | Nanostructured Surfaces | December 2022 | July 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18010853 | ANTI-CD38 ANTIBODY AND USE THEREOF | December 2022 | August 2025 | Allow | 32 | 0 | 0 | No | No |
| 18076772 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | December 2022 | December 2024 | Allow | 24 | 2 | 0 | No | No |
| 17924369 | FLUOROGENIC DIMER COMPOUND, USEFUL AS A PROBE FOR DETECTION OF ENDOGENOUS RECEPTORS | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 17982116 | COMPOSITIONS OF HYPOCHLOROUS ACID AND METHODS OF MANUFACTURE THEREOF | November 2022 | March 2025 | Allow | 28 | 3 | 0 | Yes | No |
| 17975454 | COMPOSITIONS AND METHODS FOR TREATING BIOFILMS WITHOUT INDUCING ANTIMICROBIAL RESISTANCE | October 2022 | October 2025 | Allow | 36 | 4 | 0 | No | No |
| 17917377 | B7H3 Antibodies with Chelators | October 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17953209 | COMPOSITIONS AND METHODS FOR TREATING TRANSIENT BIOFILMS | September 2022 | December 2025 | Allow | 39 | 2 | 1 | No | No |
| 17943311 | RADIOTHERAPY GEL AND METHOD OF PREPARING THE SAME | September 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17759912 | COMPOUNDS AND COMPOSITIONS FOR RETINAL INJURY DETECTION AND METHODS OF USING SAME | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17759754 | METHODS OF TREATING PSMA-POSITIVE CANCER USING RADIONUCLIDE THERAPY | July 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17857413 | MULTIMODAL SILICA-BASED NANOPARTICLES | July 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17789036 | SCAFFOLD PROTEINS AND THERAPEUTIC NANOCONJUGATES BASED ON NIDOGEN | June 2022 | January 2026 | Allow | 42 | 1 | 0 | No | No |
| 17842100 | ACETIC ACID AND HYPOCHLOROUS ACID COMPOSITIONS FOR TREATMENT OF SKIN TRAUMA | June 2022 | May 2025 | Allow | 35 | 5 | 0 | No | No |
| 17756689 | A Theranostic Probe and its Use for Targeting and/or Labeling the EGFR Kinase and/or the Cells Expressing EGFR or its Family Members | May 2022 | October 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17740549 | RADIOACTIVE YTTRIUM PHOSPHATE SUSPENSION AND METHOD OF PREPARING THE SAME | May 2022 | October 2025 | Allow | 41 | 1 | 0 | No | No |
| 17738647 | M13 PHAGE BASED GENE THERAPY PLATFORM | May 2022 | June 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17661305 | FLUORESCENT CONTRAST AGENT WITH TARGETING FUNCTION, AND PREPARATION METHOD AND USE THEREOF | April 2022 | December 2025 | Allow | 43 | 1 | 0 | No | No |
| 17755221 | TREATMENT OF PANCREATIC CANCER | April 2022 | January 2026 | Allow | 45 | 2 | 0 | No | No |
| 17768321 | SEALING MATERIAL FOR A MEDICAL IMPLANT | April 2022 | January 2026 | Allow | 45 | 2 | 0 | No | No |
| 17761579 | RADIOLABELING OF ANTI-CD45 IMMUNOGLOBULIN AND METHODS OF USE THEREOF | March 2022 | January 2026 | Allow | 46 | 1 | 0 | No | No |
| 17638559 | METHOD OF PREPARING A RADIOACTIVE YTTRIUM PHOSPHATE PARTICLE SUSPENSION | February 2022 | September 2024 | Allow | 31 | 3 | 0 | No | No |
| 17638512 | NOVEL THERANOSTIC AGENTS FOR PSMA POSITIVE CANCERS | February 2022 | May 2025 | Allow | 39 | 0 | 0 | No | No |
| 17672998 | Compositions Comprising Milk Fat Globules | February 2022 | April 2025 | Abandon | 38 | 5 | 0 | Yes | No |
| 17633536 | Targeted Nanoparticles of Well-Defined and Reproducible Sizes | February 2022 | December 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17625973 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | January 2022 | September 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17566023 | Antimicrobial Solid Surfaces and Treatments and Processes for Preparing the Same | December 2021 | December 2024 | Allow | 35 | 4 | 0 | Yes | No |
| 17566335 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | December 2021 | January 2025 | Allow | 37 | 2 | 0 | No | Yes |
| 17620312 | BIOTHIOL-ACTIVATABLE PROBE AND METHOD OF USE | December 2021 | June 2025 | Allow | 42 | 2 | 0 | No | No |
| 17617462 | SURFACE ENHANCED RAMAN SCATTERING NANOPARTICLES AND THEIR USE IN DETECTING AND IMAGING OXIDATIVE STRESS | December 2021 | September 2025 | Allow | 46 | 1 | 0 | No | No |
| 17456818 | POLYMERIC NANOPARTICLES | November 2021 | August 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17521414 | THERAPEUTIC PROTEIN-BASED NANOPARTICLES FOR TREATING CANCER | November 2021 | December 2024 | Allow | 38 | 3 | 0 | Yes | No |
| 17609536 | THERAPEUTIC PEPTIDES | November 2021 | June 2025 | Allow | 43 | 2 | 0 | No | No |
| 17517808 | Succinylcholine Chloride Prefilled Syringe | November 2021 | January 2025 | Allow | 38 | 5 | 0 | Yes | No |
| 17518353 | ANTI-PEST GUARDIAN BARRIER INCLUDING AN ARTICLE/SUBSTRATE PROTECTING DRYING OIL | November 2021 | November 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17451706 | TARGET DELIVERY OF CHEMICAL TRACERS FOR SINGLE WELL CHEMICAL TRACER TESTS | October 2021 | April 2025 | Abandon | 41 | 5 | 1 | Yes | No |
| 17603494 | FUNCTIONALIZED SILICA NANORINGS, METHODS OF MAKING SAME, AND USES THEREOF | October 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17598509 | PH-DEPENDENT COMPOSITION MATTERS USEFUL FOR STUDY AND DIAGNOSIS OF ALZHEIMER'S DISEASE | September 2021 | December 2025 | Allow | 50 | 1 | 1 | No | No |
| 17469021 | Long-acting formulations | September 2021 | June 2024 | Allow | 34 | 3 | 0 | Yes | No |
| 17446386 | APPARATUS AND METHODS FOR SEALING A VASCULAR PUNCTURE | August 2021 | June 2025 | Allow | 45 | 3 | 1 | No | No |
| 17460235 | TARGETED MAGNETIC VEHICLES AND METHOD OF USING THE SAME | August 2021 | April 2025 | Abandon | 43 | 3 | 0 | No | No |
| 17459562 | FUNCTIONALIZED SILICA NANORINGS, METHODS OF MAKING SAME, AND USES THEREOF | August 2021 | December 2025 | Allow | 52 | 2 | 1 | No | No |
| 17434363 | MODULAR METAL–ORGANIC POLYHEDRA SUPERASSEMBLY COMPOSITIONS | August 2021 | September 2024 | Allow | 37 | 1 | 0 | No | No |
| 17425401 | HIGH DENSITY LIPOPROTEIN MIMETIC NANOPARTICLES USING LIPID CONJUGATED CORE SCAFFOLDS | July 2021 | August 2025 | Allow | 49 | 2 | 1 | No | No |
| 17424084 | PSMA LIGAND TARGETED COMPOUNDS AND USES THEREOF | July 2021 | June 2024 | Allow | 35 | 0 | 0 | No | No |
| 17422414 | DRUG DELIVERY SYSTEM AND METHOD | July 2021 | February 2026 | Abandon | 55 | 4 | 0 | No | No |
| 17341765 | APPARATUS AND METHODS FOR SEALING A VASCULAR PUNCTURE | June 2021 | November 2024 | Allow | 41 | 3 | 0 | No | No |
| 17296379 | NANOCARRIER SYSTEMS FOR IMAGING AND DELIVERY OF ACTIVE AGENTS | May 2021 | September 2025 | Allow | 51 | 4 | 0 | Yes | No |
| 17294701 | RECONSTITUTED HDL NANOPARTICLES FOR DELIVERY OF RADIOACTIVE AGENTS AND USES THEREOF | May 2021 | September 2024 | Allow | 40 | 1 | 0 | No | No |
| 17322577 | MEDICAL IMAGING TECHNIQUE USING X-RAY TO NEAR-INFRARED DOWNCONVERTING NANOPOWDER | May 2021 | February 2025 | Allow | 45 | 1 | 1 | No | No |
| 17221959 | PROCESS FOR MAKING DRY AND STABLE HEMOSTATIC COMPOSITIONS | April 2021 | September 2024 | Allow | 42 | 3 | 1 | No | Yes |
| 17221203 | Catalytic Microgelators for Decoupled Control of Gelation Rate and Rigidity of Biological Gels | April 2021 | September 2024 | Allow | 41 | 5 | 0 | No | No |
| 17268952 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | February 2021 | September 2024 | Allow | 43 | 1 | 0 | No | No |
| 17263269 | METHOD FOR ANALYZING THE PLATELETS OF A BLOOD SAMPLE | January 2021 | November 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 17263052 | BIOCOMPATIBLE ULTRASONIC COUPLING AGENT FOR ENDOSCOPE AND USE THEREOF | January 2021 | April 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17258846 | METHODS AND COMPOSITIONS FOR DELIVERY OF AGENTS ACROSS THE BLOOD-BRAIN BARRIER | January 2021 | May 2025 | Allow | 52 | 2 | 1 | No | No |
| 17047299 | NANOMOLECULES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | October 2020 | May 2025 | Allow | 55 | 3 | 0 | No | No |
| 17066418 | Magnetic Microwires for Energy-Transporting Biomedical Applications | October 2020 | March 2025 | Allow | 53 | 3 | 1 | No | No |
| 17027286 | FLUOROPHORES FOR SUPER-RESOLUTION IMAGING | September 2020 | June 2025 | Allow | 56 | 5 | 1 | Yes | Yes |
| 17018314 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | September 2020 | November 2024 | Allow | 50 | 5 | 0 | Yes | No |
| 16983171 | Method of enhancing the antimicrobial action of systemically administered antibiotics | August 2020 | August 2024 | Allow | 60 | 3 | 0 | Yes | No |
| 16936909 | STABLE COMPOSITIONS OF MRNA-LOADED LIPID NANOPARTICLES AND PROCESSES OF MAKING | July 2020 | June 2024 | Allow | 47 | 5 | 0 | No | No |
| 16960393 | COMPOSITIONS AND METHODS RELATING TO MACROPHAGES AND/OR MONOCYTES WITH ADHERED PARTICLES | July 2020 | May 2025 | Allow | 58 | 4 | 1 | No | No |
| 16958647 | DRUG DELIVERY SYSTEMS FOR TREATMENT OF INFECTIONS | June 2020 | October 2025 | Allow | 60 | 4 | 1 | No | No |
| 16761114 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | May 2020 | February 2025 | Allow | 58 | 3 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CABRAL, ROBERT S.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CABRAL, ROBERT S works in Art Unit 1614 and has examined 88 patent applications in our dataset. With an allowance rate of 85.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner CABRAL, ROBERT S's allowance rate of 85.2% places them in the 62% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by CABRAL, ROBERT S receive 3.26 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CABRAL, ROBERT S is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +2.9% benefit to allowance rate for applications examined by CABRAL, ROBERT S. This interview benefit is in the 24% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 22.6% of applications are subsequently allowed. This success rate is in the 29% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 71.4% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.